EMAIL THIS PAGE TO A FRIEND

Arthritis & rheumatology (Hoboken, N.J.)

Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis.


PMID 24782183

Abstract

The small molecule halofuginone has been shown to inhibit fibrosis, angiogenesis, and tumor progression. This study was undertaken to evaluate the effects of halofuginone in preventing autoimmune arthritis in mice. The effects of halofuginone on joint diseases were assessed by clinical scoring and histologic analysis. Protein expression levels were confirmed by immunohistochemistry, enzyme-linked immunosorbent assay, flow cytometry, and/or Western blotting. The expression levels of messenger RNA (mRNA) for various molecules were determined by real-time polymerase chain reaction (PCR). Proliferation of osteoclast precursors was assessed by bromodeoxyuridine uptake. Osteoclast differentiation and activity were determined by quantifying tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells and area of resorbed bone. Treatment with halofuginone suppressed the development of autoimmune arthritis and reciprocally regulated Th17 cells and FoxP3+ Treg cells. These effects of halofuginone on Th17 differentiation involved increased signaling of ERK and reduction of STAT-3 and NF-ATc1 expression. Furthermore, halofuginone induced the expression of indoleamine 2,3-dioxygenase (IDO) in dendritic cells, leading to reduced production of Th17 cells. In addition, halofuginone prevented the formation and activity of osteoclasts through suppression of transcription factors, such as activator protein 1 and NF-ATc1, and inhibited cell cycle arrest by the committed osteoclast precursors via expression of Ccnd1 encoding cyclin D1. Taken together, our results suggest that halofuginone is a promising therapeutic agent for the treatment of Th17 cell-mediated inflammatory diseases and bone diseases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A9400
7-Aminoactinomycin D, ~97% (HPLC), powder
C62H87N13O16
PRS4877
Anti-IL-17 (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS4887
Anti-IL-17 (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2502114
Anti-IL17A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502115
Anti-IL17A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA052258
Anti-IL17A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1100153
Anti-NFATC1 (296-310) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB2101576
Anti-NFATC1 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2101577
Anti-NFATC1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2105028
Anti-NFATC1 antibody produced in rabbit, affinity isolated antibody
SAB2104069
Anti-NFATC1, (N-terminal) antibody produced in rabbit, affinity isolated antibody
SAB4700360 Monoclonal Anti-CD25 antibody produced in mouse, clone MEM-181, purified immunoglobulin, buffered aqueous solution
SAB4700365 Monoclonal Anti-CD25 antibody produced in mouse, clone MEM-140, purified immunoglobulin, buffered aqueous solution
SAB1305503
MONOCLONAL ANTI-CD25 antibody produced in mouse, clone 7G7B6, crude ascites, buffered aqueous solution
SAB3701439
Monoclonal Anti-IL-17A antibody produced in mouse, clone 4H1524.1, purified immunoglobulin
SAB3701458
Monoclonal Anti-IL-17A antibody produced in rat, clone 20B4.G10.F5, purified immunoglobulin
WH0003559M4
Monoclonal Anti-IL2RA antibody produced in mouse, clone 1D6, purified immunoglobulin, buffered aqueous solution